Optimizing Dosing and Regulatory Outcomes in Duchenne Muscular Dystrophy (DMD) Drug Development
Certara supported DMD drug development for Givinostat, helping Italfarmaco with pharmacometric and regulatory strategy.
Certara2025 年 7 月 29 日
MIDD Strategies for Preclinical and Clinical Translation: A Collaboration Between Clinical Pharmacologists and Modeling Disciplines
Learn how clinical pharmacologists and modeling experts collaborate to improve preclinical-to-clinical translation.
Certara2025 年 7 月 29 日
ADNCA Explained: The Next Generation of Non-Compartmental Analysis and the Top Questions Answered
ADNCA is transforming non-compartmental analysis by standardizing workflows, enhancing regulatory confidence, and enabling scalable automation.…
Certara2025 年 7 月 23 日
MIDD can ease pediatric & rare disease drug loss in Japan
Certara tackles pediatric cancer and rare disease drug loss in Japan by advocating MIDD, which…
Certara2025 年 7 月 8 日
Accelerating Oncology Drug FDA RTOR Submission with Project Management Services
Discover how Certara’s dedicated project management and pharmacometric support helped an emerging biotech company fast-track…
Certara2025 年 7 月 2 日
How Model-informed drug development rescue projects from a risky situation
Discover how Certara’s integrated approach to model-informed drug development helps clients navigate regulatory challenges, achieve…
Certara2025 年 6 月 26 日
From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara
Discover the Real-World Impact of Model-Based Meta-Analysis. Hear from experts, see case studies to advance…
Certara2025 年 6 月 18 日
